CD22 — Drug Target

All drugs that target CD22 — marketed and clinical-stage. Includes 9 drug classes acting on this target.

Drug classes

Antibody-drug conjugate (ADC) · CD22-directed Immunoconjugate [EPC] · Monoclonal antibody · CD22-targeting monoclonal antibody · Immunotoxin · CD22-targeting antibody-drug conjugate · Monoclonal antibody-drug conjugate · CAR-T cell therapy · CAR T-cell therapy

Marketed (6)

• Besponsa · Pfizer Inc. · Antibody-drug conjugate (ADC) · Oncology
  CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis.
• Besponsa · Pfizer · CD22-directed Immunoconjugate [EPC] · Oncology
  Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells.
• INOTUZUMAB OZOGAMICIN · CD22-directed Immunoconjugate [EPC] · Oncology
  Inotuzumab ozogamicin is a CD22-directed antibody-drug conjugate that binds to CD22 on tumor cells, internalizes, and releases a cytotoxic agent causing DNA damage and cell death.
• Besponsa · Pfizer · Antibody-drug conjugate (ADC) · Oncology
  CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis.
• Inotuzumab ozogamicin-dose level 1 · Pfizer · Antibody-drug conjugate (ADC) · Oncology
  Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody conjugated to a cytotoxic calicheamicin payload that binds to CD22 on B-cell lymphomas and delivers cell-killing chemotherapy directly to tumor cells.
• Inotuzumab ozogamicin (INO) · Charite University, Berlin, Germany · Antibody-drug conjugate (ADC) · Oncology
  Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody conjugated to a cytotoxic calicheamicin payload that binds to CD22 on B-cell lymphomas and delivers cell-killing toxin directly to tumor cells.

Phase 3 pipeline (1)

• SR-B + Epratuzumab · Charite University, Berlin, Germany · Monoclonal antibody · Immunology
  SR-B combined with epratuzumab targets B cell surface antigens to modulate immune response in autoimmune and inflammatory conditions.

Phase 2 pipeline (3)

• EVO301 · Evommune, Inc. · CD22-targeting monoclonal antibody · Immunology
  EVO301 is a monoclonal antibody targeting CD22.
• Anti-CD22 Immunotoxin · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Immunotoxin · Oncology
  An immunotoxin that binds to CD22 on B-cell lymphomas and delivers a cytotoxic payload to kill malignant cells.
• I-DXd · Merck Sharp & Dohme LLC · CD22-targeting antibody-drug conjugate · Oncology
  Targeting CD22 with antibody-drug conjugate

Phase 1 pipeline (3)

• 89Zr-DFO-girentuximab · NYU Langone Health · Monoclonal antibody-drug conjugate · Oncology
  Targeting CD22
• :Anti-CD22-CAR · Kecellitics Biotech Company Ltd · CAR-T cell therapy · Oncology
  Chimeric antigen receptor targeting CD22
• Anti-CD22 CAR NK Cells · Allife Medical Science and Technology Co., Ltd. · CAR T-cell therapy · Oncology
  Targeting CD22 on B cells